Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
|Videos|January 13, 2023
Dr. Ravi on unmet needs in PSMA-targeted paradigm
Author(s)Urology Times staff
Advertisement
Praful Ravi, MB, BChir, MRCP, discusses remaining needs and next steps with PSMA-targeted agents in prostate cancer.Ravi is a medical oncologisxt at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School.
Advertisement
Related to this article
The target enrollment goal has been reached in the phase 3 BiPASS study, evaluating PSMA-PET plus MRI for prostate cancer detection.
Advertisement
Advertisement
Trending on Urology Times
1
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
2
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
3
Topical sildenafil cream associated with lower systemic exposure vs oral sildenafil
4
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
5